{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T19:31:19Z","timestamp":1694633479623},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2008,7,1]],"date-time":"2008-07-01T00:00:00Z","timestamp":1214870400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2008,7,1]],"date-time":"2008-07-01T00:00:00Z","timestamp":1214870400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Allergy Asthma Rep"],"published-print":{"date-parts":[[2008,7]]},"DOI":"10.1007\/s11882-008-0055-1","type":"journal-article","created":{"date-parts":[[2008,10,12]],"date-time":"2008-10-12T02:30:25Z","timestamp":1223778625000},"page":"348-353","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Immunomodulatory treatment for dermatomyositis"],"prefix":"10.1007","volume":"8","author":[{"given":"Jeffrey P.","family":"Callen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,10,11]]},"reference":[{"key":"55_CR1","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.clindermatol.2006.07.001","volume":"24","author":"J.P. Callen","year":"2006","unstructured":"Callen JP, Wortmann RL: Dermatomyositis. Clin Dermatol 2006, 24:363\u2013373.","journal-title":"Clin Dermatol"},{"key":"55_CR2","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/S0140-6736(99)05157-0","volume":"355","author":"J.P. Callen","year":"2000","unstructured":"Callen JP: Dermatomyositis. Lancet 2000, 355:53\u201357.","journal-title":"Lancet"},{"key":"55_CR3","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1056\/NEJM197502132920706","volume":"292","author":"A. Bohan","year":"1975","unstructured":"Bohan A, Peter JB: Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975, 292:344\u2013347.","journal-title":"N Engl J Med"},{"key":"55_CR4","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJM197502202920807","volume":"292","author":"A. Bohan","year":"1975","unstructured":"Bohan A, Peter JB: Polymyositis and dermatomyositis (second of two parts). N Engl J Med 1975, 292:403\u2013407.","journal-title":"N Engl J Med"},{"key":"55_CR5","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.jaad.2005.10.041","volume":"54","author":"P. Gerami","year":"2006","unstructured":"Gerami P, Schope JM, McDonald L, et al.: A systematic review of adult-onset clinically amyopathic dermatomyositis (dermatomyositis sin\u00e9 myositis): a missing link within the spectrum of the idiopathic inflammatory myopathies. J Am Acad Dermatol 2006, 54:597\u2013613.","journal-title":"J Am Acad Dermatol"},{"key":"55_CR6","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.jpeds.2005.10.032","volume":"148","author":"L.M. Pachman","year":"2006","unstructured":"Pachman LM, Abbott K, Sinacore JM, et al.: Duration of illness is an important variable for untreated children with juvenile dermatomyositis. J Pediatr 2006, 148:247\u2013253.","journal-title":"J Pediatr"},{"key":"55_CR7","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1002\/art.23340","volume":"59","author":"A.M. Huber","year":"2008","unstructured":"Huber AM, Dugan EM, Lachenbruch PA, et al.: Preliminary validation and clinical meaning of the cutaneous assessment tool in juvenile dermatomyositis. Arthritis Rheum 2008, 59:214\u2013221.","journal-title":"Arthritis Rheum"},{"key":"55_CR8","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1111\/j.1365-2133.2007.08342.x","volume":"158","author":"C.L. Carroll","year":"2008","unstructured":"Carroll CL, Lang W, Snively B, et al.: Development and validation of the Dermatomyositis Skin Severity Index. Br J Dermatol 2008, 158:345\u2013350.","journal-title":"Br J Dermatol"},{"key":"55_CR9","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s00403-007-0813-2","volume":"300","author":"E. Gaines","year":"2008","unstructured":"Gaines E, Werth VP: Development of outcome measures for autoimmune dermatoses. Arch Dermatol Res 2008, 300:3\u20139.","journal-title":"Arch Dermatol Res"},{"key":"55_CR10","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1093\/rheumatology\/keg427","volume":"43","author":"D.A. Isenberg","year":"2004","unstructured":"Isenberg DA, Allen E, Farrell V et al.: International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease. Rheumatology (Oxford) 2004, 43:49\u201354.","journal-title":"Rheumatology (Oxford)"},{"key":"55_CR11","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1136\/pgmj.2005.038455","volume":"82","author":"A.C. Cordiero","year":"2006","unstructured":"Cordiero AC, Isenberg DA: Treatment of inflammatory myopathies. Postgrad Med J 2006, 82:417\u2013424.","journal-title":"Postgrad Med J"},{"key":"55_CR12","volume-title":"Evidence Based Dermatology","author":"D.F. Fiorentino","year":"2008","unstructured":"Fiorentino DF, Callen JP: Dermatomyositis. In Evidence Based Dermatology. Edited by Williams H, Bigby M, Diepgen T, et al. London: BMJ Press; 2008."},{"key":"55_CR13","first-page":"545","volume":"43","author":"R.K. Winkelmann","year":"1968","unstructured":"Winkelmann RK, Mulder DW, Lambert EH, et al.: Course of dermatomyositis-polymyositis: comparison of untreated and cortisone-treated patients. Mayo Clin Proc 1968, 43:545\u2013556.","journal-title":"Mayo Clin Proc"},{"key":"55_CR14","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1002\/1529-0131(200012)13:6<360::AID-ART5>3.0.CO;2-Q","volume":"13","author":"M.S. Klein-Gitelman","year":"2000","unstructured":"Klein-Gitelman MS, Waters T, Pachman LM: The economic impact of intermittent high-dose intravenous versus oral corticosteroid treatment of juvenile dermatomyositis. Arthritis Care Res 2000, 13:360\u2013368.","journal-title":"Arthritis Care Res"},{"key":"55_CR15","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1097\/00005792-197707000-00001","volume":"56","author":"A. Bohan","year":"1977","unstructured":"Bohan A, Peter JB, Bowman RL, Pearson CM: Computer-assisted analysis of 153 patients with polymyositis and dermatomyositis. Medicine (Baltimore) 1977, 56:255\u2013286.","journal-title":"Medicine (Baltimore)"},{"key":"55_CR16","first-page":"441","volume":"17","author":"A. Nzeusseu","year":"1999","unstructured":"Nzeusseu A, Brion F, Lef\u00e8bvre C, et al.: Functional outcome of myositis patients: can a low-dose glucocorticoid regimen achieve good functional results?\n                           Clin Exp Rheumatol 1999, 17:441\u2013446.","journal-title":"Clin Exp Rheumatol"},{"key":"55_CR17","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/S0190-9622(98)70496-7","volume":"38","author":"M.A. Dawkins","year":"1998","unstructured":"Dawkins MA, Jorizzo JL, Walker FO, et al.: Dermatomyositis: a dermatology-based case series. J Am Acad Dermatol, 1998, 38:397\u2013404.","journal-title":"J Am Acad Dermatol"},{"key":"55_CR18","doi-asserted-by":"crossref","first-page":"365","DOI":"10.7326\/0003-4819-92-3-365","volume":"92","author":"T.W. Bunch","year":"1980","unstructured":"Bunch TW, Worthington JS, Combs JJ, et al.: Azathioprine with prednisone for polymyositis. A controlled, clinical trial. Ann Intern Med 1980, 92:365\u2013369.","journal-title":"Ann Intern Med"},{"issue":"Suppl1","key":"55_CR19","first-page":"S53","volume":"199","author":"J. Miller","year":"2002","unstructured":"Miller J, Walsh Y, Saminaden S, et al.: Randomised double blind controlled trial of methotrexate and steroids compared with azathioprine and steroids in the treatment of idiopathic inflammatory myopathy. J Neurological Sci 2002, 199(Suppl 1):S53.","journal-title":"J Neurological Sci"},{"key":"55_CR20","doi-asserted-by":"publisher","first-page":"3570","DOI":"10.1002\/art.21378","volume":"52","author":"A.V. Ramanan","year":"2005","unstructured":"Ramanan, AV, Campbell-Webster N, Ota S, et al.: The effectiveness of treating juvenile dermatomyositis with methotrexate and aggressively tapered corticosteroids. Arthritis Rheum 2005, 52:3570\u20133578.","journal-title":"Arthritis Rheum"},{"key":"55_CR21","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1002\/1529-0131(199803)41:3<392::AID-ART3>3.0.CO;2-X","volume":"41","author":"L. Villalba","year":"1998","unstructured":"Villalba L, Adams EM, Sherman JB, et al.: Treatment of refractory myositis: a randomized crossover study of two new cytotoxic regimens. Arthritis Rheum 1998, 41:392\u2013399.","journal-title":"Arthritis Rheum"},{"key":"55_CR22","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1056\/NEJM199305063281806","volume":"328","author":"O.W. Kamel","year":"1993","unstructured":"Kamel OW, van de Rijn M, Weiss LM, et al.: Brief report: reversible lymphomas associated with Epstein-Barr virus occurring during methotrexate therapy for rheumatoid arthritis and dermatomyositis. N Engl J Med 1993, 328:1317\u20131321.","journal-title":"N Engl J Med"},{"issue":"2Suppl","key":"55_CR23","doi-asserted-by":"publisher","first-page":"S124","DOI":"10.1016\/j.jaad.2004.03.020","volume":"51","author":"M.A. Waldman","year":"2004","unstructured":"Waldman MA, Callen JP: Self-resolution of Epstein-Barr virus-associated B-cell lymphoma in a patient with dermatomyositis following withdrawal of mycophenolate mofetil and methotrexate. J Am Acad Dermatol 2004, 51(2 Suppl):S124\u2013S130.","journal-title":"J Am Acad Dermatol"},{"key":"55_CR24","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1002\/art.1780240107","volume":"24","author":"T.W. Bunch","year":"1981","unstructured":"Bunch TW: Prednisone and azathioprine for polymyositis. Arthritis Rheum 1981, 24:45\u201348.","journal-title":"Arthritis Rheum"},{"key":"55_CR25","first-page":"1542","volume":"27","author":"A.C. Gelber","year":"2000","unstructured":"Gelber AC, Nousari HC, Wigley FM: Mycophenolate mofetil in the treatment of severe skin manifestations of dermatomyositis: a series of 4 cases. J Rheumatol 2000, 27:1542\u20131545.","journal-title":"J Rheumatol"},{"key":"55_CR26","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1159\/000051674","volume":"202","author":"A.K. Tausche","year":"2001","unstructured":"Tausche AK, Meurer M: Mycophenolate mofetil for dermatomyositis. Dermatology 2001, 202:341\u2013343.","journal-title":"Dermatology"},{"key":"55_CR27","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1093\/rheumatology\/keh499","volume":"44","author":"V. Majithia","year":"2005","unstructured":"Majithia V, Harisdangkul V: Mycophenolate mofetil (Cell-Cept): an alternative therapy for autoimmune inflammatory myopathy. Rheumatology (Oxford) 2005, 44:386\u2013389.","journal-title":"Rheumatology (Oxford)"},{"key":"55_CR28","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1001\/archderm.142.1.65","volume":"142","author":"J.C. Edge","year":"2006","unstructured":"Edge JC, Oultand JD, Dempsey JR, Callen JP: Mycophenolate mofetil as an effective corticosteroid-sparing therapy for recalcitrant dermatomyositis. Arch Dermatol 2006, 142:65\u201369.","journal-title":"Arch Dermatol"},{"key":"55_CR29","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1212\/01.wnl.0000208416.32471.c0","volume":"66","author":"J. Rowin","year":"2006","unstructured":"Rowin J, Amato AA, Deisher N, et al.: Mycophenolate mofetil in dermatomyositis: is it safe?\n                           Neurology 2006, 66:1245\u20131247.","journal-title":"Neurology"},{"key":"55_CR30","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1080\/030097400750001897","volume":"29","author":"J. Vencovsky","year":"2000","unstructured":"Vencovsky J, Jarosov\u00e1 K, Mach\u00e1cek S, et al.: Cyclosporine A versus methotrexate in the treatment of polymyositis and dermatomyositis. Scand J Rheumatol 2000, 29:95\u2013102.","journal-title":"Scand J Rheumatol"},{"key":"55_CR31","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1002\/art.21240","volume":"52","author":"M.R. Wilkes","year":"2005","unstructured":"Wilkes MR, Sereika SM, Fertig N, et al.: Treatment of antisynthetase-associated interstitial lung disease with tacrolimus. Arthritis Rheum 2005, 52:2439\u20132446.","journal-title":"Arthritis Rheum"},{"key":"55_CR32","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1002\/art.1780360305","volume":"36","author":"P.A. Sinoway","year":"1993","unstructured":"Sinoway PA, Callen JP: Chlorambucil. An effective corticosteroid-sparing agent for patients with recalcitrant dermatomyositis. Arthritis Rheum 1993, 36:319\u2013324.","journal-title":"Arthritis Rheum"},{"key":"55_CR33","first-page":"352","volume":"26","author":"E.M. Adams","year":"1999","unstructured":"Adams EM, Pucino F, Yarboro C, et al.: A pilot study: use of fludarabine for refractory dermatomyositis and polymyositis, and examination of endpoint measures. J Rheumatol 1999, 26:352\u2013360.","journal-title":"J Rheumatol"},{"key":"55_CR34","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1093\/rheumatology\/keh082","volume":"43","author":"P. Riley","year":"2004","unstructured":"Riley P, Maillard SM, Wedderburn LR, et al.: Intravenous cyclophosphamide pulse therapy in juvenile dermatomyositis. A review of efficacy and safety. Rheumatology (Oxford) 2004, 43:491\u2013496.","journal-title":"Rheumatology (Oxford)"},{"key":"55_CR35","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1056\/NEJM199312303292704","volume":"329","author":"M.C. Dalakas","year":"1993","unstructured":"Dalakas MC, Illa I, Dambrosia JM, et al.: A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 1993, 329:1993\u20132000.","journal-title":"N Engl J Med"},{"key":"55_CR36","first-page":"29","volume":"10","author":"I. Gottfried","year":"2000","unstructured":"Gottfried I., Seeber A, Anegg B, et al.: High dose intravenous immunoglobulin (IVIG) in dermatomyositis: clinical responses and effect on sIL-2R levels. Eur J Dermatol 2000, 10:29\u201335.","journal-title":"Eur J Dermatol"},{"key":"55_CR37","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1002\/art.20849","volume":"52","author":"T.D. Levine","year":"2005","unstructured":"Levine TD: Rituximab in the treatment of dermatomyositis: an open-label pilot study. Arthritis Rheum 2005, 52:601\u2013607.","journal-title":"Arthritis Rheum"},{"key":"55_CR38","first-page":"1021","volume":"33","author":"E.H. Noss","year":"2006","unstructured":"Noss EH, Hausner-Sypek DL, Weinblatt ME: Rituximab as therapy for refractory polymyositis and dermatomyositis. J Rheumatol 2006, 33:1021\u20131026.","journal-title":"J Rheumatol"},{"key":"55_CR39","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1001\/archderm.143.6.763","volume":"143","author":"L. Chung","year":"2007","unstructured":"Chung L, Genovese MC, Fiorentino DF: A pilot trial of rituximab in the treatment of patients with dermatomyositis. Arch Dermatol 2007, 143:763\u2013767.","journal-title":"Arch Dermatol"},{"key":"55_CR40","doi-asserted-by":"publisher","first-page":"3107","DOI":"10.1002\/art.22856","volume":"56","author":"M.A. Cooper","year":"2007","unstructured":"Cooper MA, Willingham DL, Brown DE, et al.: Rituximab for the treatment of juvenile dermatomyositis: a report of four pediatric patients. Arthritis Rheum 2007, 56:3107\u20133111.","journal-title":"Arthritis Rheum"},{"key":"55_CR41","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.jaad.2006.05.068","volume":"56","author":"H.V. Dinh","year":"2007","unstructured":"Dinh HV, McCormack C, Hall S, Prince HM: Rituximab for the treatment of the skin manifestations of dermatomyositis: a report of 3 cases. J Am Acad Dermatol 2007, 56:148\u2013153.","journal-title":"J Am Acad Dermatol"},{"key":"55_CR42","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1136\/ard.2005.048744","volume":"65","author":"P. Efthimiou","year":"2006","unstructured":"Efthimiou P, Schwartzman S, Kagen LJ: Possible role for tumour necrosis factor inhibitors in the treatment of resistant dermatomyositis and polymyositis: a retrospective study of eight patients. Ann Rheum Dis 2006, 65:1233\u20131236.","journal-title":"Ann Rheum Dis"},{"key":"55_CR43","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1007\/s10067-006-0325-z","volume":"26","author":"S. Dold","year":"2007","unstructured":"Dold S, Justiniano ME, Marquez J, Espinoza LR: Treatment of early and refractory dermatomyositis with infliximab: a report of two cases. Clin Rheumatol 2007, 26:1186\u20131188.","journal-title":"Clin Rheumatol"},{"key":"55_CR44","first-page":"1802","volume":"33","author":"F. Iannone","year":"2006","unstructured":"Iannone F, Scioscia C, Falappone PC, et al.: Use of etanercept in the treatment of dermatomyositis: a case series. J Rheumatol 2006, 33:1802\u20131804.","journal-title":"J Rheumatol"},{"key":"55_CR45","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1159\/000114036","volume":"59","author":"G.J. Hengstman","year":"2008","unstructured":"Hengstman GJ, De Bleecker JL, Feist E, et al.: Open-label trial of anti-TNF-alpha in dermato-and polymyositis treated concomitantly with methotrexate. Eur Neurol 2008, 59:159\u2013163.","journal-title":"Eur Neurol"},{"key":"55_CR46","doi-asserted-by":"publisher","first-page":"341","DOI":"10.2165\/00128071-200607060-00002","volume":"7","author":"R.D. Quain","year":"2006","unstructured":"Quain RD, Werth VP: Management of cutaneous dermatomyositis: current therapeutic options. Am J Clin Dermatol 2006, 7:341\u2013351.","journal-title":"Am J Clin Dermatol"},{"key":"55_CR47","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1080\/09546630310018509","volume":"15","author":"C.B. Hollar","year":"2004","unstructured":"Hollar CB, Jorizzo JL: Topical tacrolimus 0.1% ointment for refractory skin disease in dermatomyositis: a pilot study. J Dermatolog Treat 2004, 15:35\u201339.","journal-title":"J Dermatolog Treat"},{"key":"55_CR48","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/S0190-9622(84)80263-7","volume":"10","author":"T.Y. Woo","year":"1984","unstructured":"Woo TY, Callen JP, Voorhees JJ, et al.: Cutaneous lesions of dermatomyositis are improved by hydroxychloroquine. J Am Acad Dermatol 1984, 10:592\u2013600.","journal-title":"J Am Acad Dermatol"},{"key":"55_CR49","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1001\/archderm.141.7.855","volume":"141","author":"G.C. Ang","year":"2005","unstructured":"Ang GC, Werth VP: Combination antimalarials in the treatment of cutaneous dermatomyositis: a retrospective study. Arch Dermatol 2005, 141:855\u2013859.","journal-title":"Arch Dermatol"},{"issue":"5Pt1","key":"55_CR50","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/0190-9622(95)91455-2","volume":"32","author":"M.E. Zieglschmid-Adams","year":"1995","unstructured":"Zieglschmid-Adams ME, Pandya AG, Cohen SB, Sontheimer RD: Treatment of dermatomyositis with methotrexate. J Am Acad Dermatol 1995, 32(5 Pt 1):754\u2013757.","journal-title":"J Am Acad Dermatol"},{"key":"55_CR51","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S0190-9622(97)70327-X","volume":"36","author":"J.S. Kasteler","year":"1997","unstructured":"Kasteler JS, Callen JP: Low-dose methotrexate administered weekly is an effective corticosteroid-sparing agent for the treatment of the cutaneous manifestations of dermatomyositis. J Am Acad Dermatol 1997, 36:67\u201371.","journal-title":"J Am Acad Dermatol"},{"key":"55_CR52","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.jaad.2007.08.014","volume":"58","author":"J.S. Boswell","year":"2008","unstructured":"Boswell JS, Costner M: Leflunomide as adjuvant treatment of dermatomyositis. J Am Acad Dermatol 2008, 58:403\u2013406.","journal-title":"J Am Acad Dermatol"},{"key":"55_CR53","doi-asserted-by":"publisher","first-page":"254","DOI":"10.2340\/00015555-0058","volume":"86","author":"A. Huber","year":"2006","unstructured":"Huber A, Gaffal E, Bieber T, et al.: Treatment of recalcitrant dermatomyositis with efalizumab. Acta Derm Venereol 2006, 86:254\u2013255.","journal-title":"Acta Derm Venereol"},{"key":"55_CR54","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1001\/archderm.142.1.70","volume":"142","author":"D. Sereda","year":"2006","unstructured":"Sereda D, Werth VP: Improvement in dermatomyositis rash associated with the use of antiestrogen medication. Arch Dermatol 2006, 142:70\u201372.","journal-title":"Arch Dermatol"},{"key":"55_CR55","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1001\/archderm.138.9.1231","volume":"138","author":"M.T. Pelle","year":"2002","unstructured":"Pelle MT, Callen JP: Adverse cutaneous reactions to hydroxychloroquine are more common in patients with dermatomyositis than in patients with cutaneous lupus erythematosus. Arch Dermatol 2002, 138:1231\u20131233; discussion 1233.","journal-title":"Arch Dermatol"},{"key":"55_CR56","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1002\/art.22687","volume":"57","author":"Y.L. Chung","year":"2007","unstructured":"Chung YL, Alexanderson H, Pipitone N, et al.: Creatine supplements in patients with idiopathic inflammatory myopathies who are clinically weak after conventional pharmacologic treatment: six-month, double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2007, 57:694\u2013702.","journal-title":"Arthritis Rheum"}],"container-title":["Current Allergy and Asthma Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11882-008-0055-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11882-008-0055-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11882-008-0055-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11882-008-0055-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T10:20:39Z","timestamp":1659090039000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11882-008-0055-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,7]]},"references-count":56,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2008,7]]}},"alternative-id":["55"],"URL":"https:\/\/doi.org\/10.1007\/s11882-008-0055-1","relation":{},"ISSN":["1529-7322","1534-6315"],"issn-type":[{"value":"1529-7322","type":"print"},{"value":"1534-6315","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,7]]},"assertion":[{"value":"11 October 2008","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}